CA2832992A1 - Prostacycline et analogues de celle-ci administres pendant une chirurgie pour la prevention et le traitement d'une fuite capillaire - Google Patents

Prostacycline et analogues de celle-ci administres pendant une chirurgie pour la prevention et le traitement d'une fuite capillaire Download PDF

Info

Publication number
CA2832992A1
CA2832992A1 CA2832992A CA2832992A CA2832992A1 CA 2832992 A1 CA2832992 A1 CA 2832992A1 CA 2832992 A CA2832992 A CA 2832992A CA 2832992 A CA2832992 A CA 2832992A CA 2832992 A1 CA2832992 A1 CA 2832992A1
Authority
CA
Canada
Prior art keywords
treatment
prostacyclin
surgery
administration
previous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2832992A
Other languages
English (en)
Inventor
Par Johansson
Sisse Rye OSTROWSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigshospitalet
Original Assignee
Rigshospitalet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigshospitalet filed Critical Rigshospitalet
Publication of CA2832992A1 publication Critical patent/CA2832992A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2832992A 2011-04-19 2012-03-30 Prostacycline et analogues de celle-ci administres pendant une chirurgie pour la prevention et le traitement d'une fuite capillaire Abandoned CA2832992A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161476814P 2011-04-19 2011-04-19
DKPA201170191 2011-04-19
US61/476,814 2011-04-19
DKPA201170191 2011-04-19
PCT/DK2012/050100 WO2012143012A1 (fr) 2011-04-19 2012-03-30 Prostacycline et analogues de celle-ci administrés pendant une chirurgie pour la prévention et le traitement d'une fuite capillaire

Publications (1)

Publication Number Publication Date
CA2832992A1 true CA2832992A1 (fr) 2012-10-26

Family

ID=44146755

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2832992A Abandoned CA2832992A1 (fr) 2011-04-19 2012-03-30 Prostacycline et analogues de celle-ci administres pendant une chirurgie pour la prevention et le traitement d'une fuite capillaire

Country Status (9)

Country Link
US (1) US20140044797A1 (fr)
EP (1) EP2699243A1 (fr)
JP (1) JP2014514310A (fr)
KR (1) KR20140053881A (fr)
CN (1) CN103635195A (fr)
AU (1) AU2012244650A1 (fr)
BR (1) BR112013027009A2 (fr)
CA (1) CA2832992A1 (fr)
WO (1) WO2012143012A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104721825B (zh) 2009-06-12 2019-04-12 曼金德公司 具有确定比表面积的二酮哌嗪颗粒
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP3712142B1 (fr) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Promédicaments de tréprostinil
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
WO2016123163A2 (fr) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarqueurs de maladies vasculaires
EP3278112B1 (fr) 2015-03-29 2021-09-22 Endothel Pharma ApS Composition comprenant de la prostacycline ou des analogues de celle-ci pour le traitement des patients souffrant d'une maladie critique aiguë
US9943572B2 (en) * 2015-04-08 2018-04-17 Microvascular Health Solutions, LLC Synergistic glycocalyx treatment compositions and methods
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
JOP20190204A1 (ar) * 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
WO2018208846A1 (fr) * 2017-05-08 2018-11-15 Microvascular Health Solutions, LLC Compositions, systèmes et procédés d'évaluation et d'amélioration de la santé vasculaire et traitements impliquant ceux-ci
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
CN113133996B (zh) * 2020-01-20 2023-07-04 山东威高宏瑞医学科技有限公司 乙酰半胱氨酸或其化学上可接受的盐/酯在制备结缔组织的分离制剂中的应用
CN112755070B (zh) * 2021-02-02 2022-03-08 江苏省苏北人民医院 乌药提取物在制备治疗急性呼吸窘迫综合征药物中的应用
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011006995A (es) 2008-12-30 2011-09-27 Thrombologic Aps Metodos para identificar pacientes criticamente enfermos en riesgo incrementado de desarrollar nsuficiencia organica y compuestos para el tratamiento de la misma.
KR20140025303A (ko) * 2010-10-01 2014-03-04 릭스하스피탈렛 급성 외상성 응고장애 및 소생된 심박 정지의 예방 또는 치료에 사용되는 내피 무결성을 조절／보존할 수 있는 화합물

Also Published As

Publication number Publication date
US20140044797A1 (en) 2014-02-13
KR20140053881A (ko) 2014-05-08
EP2699243A1 (fr) 2014-02-26
JP2014514310A (ja) 2014-06-19
AU2012244650A1 (en) 2013-11-21
WO2012143012A1 (fr) 2012-10-26
BR112013027009A2 (pt) 2016-12-27
CN103635195A (zh) 2014-03-12

Similar Documents

Publication Publication Date Title
US20140044797A1 (en) Prostacyclin and analogs thereof administered during surgery for prevention and treatment of capillary leakage
AU2011307494B2 (en) Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
US20150057325A1 (en) Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
Reed et al. Edema and fluid dynamics in connective tissue remodelling
CN102271685A (zh) 鉴定发展成器官功能衰竭的风险提高的危重患者的方法及用于其治疗的化合物
EP2207537B1 (fr) Effet systémique pro-hémostatique de sympathicomimétiques à effets antagonistes sur les récepteurs alfa-adrénergiques et/ou bêta-adrénergiques du système nerveux sympathique, associé à une meilleure résistance des caillots
Boldt Volume therapy in cardiac surgery: does the kind of fluid matter?
Schramko et al. Comparison of the effect of 6% hydroxyethyl starch and gelatine on cardiac and stroke volume index: a randomized, controlled trial after cardiac surgery
JP2024517355A (ja) 血管内皮炎の治療において使用するための中間分子量ヘパリン
ES2898424T3 (es) Una composición que comprende prostaciclina o sus análogos para tratamiento de pacientes críticamente enfermos de modo agudo
Boldt et al. RETRACTED: Volume Replacement With a Balanced Hydroxyethyl Starch (HES) Preparation in Cardiac Surgery Patients
Boldt Volume therapy in cardiac surgery
CN115996710B (zh) 用于治疗组织缺氧和脓毒症的包含l-三碘甲腺原氨酸（t3）的药物组合物
Wong et al. Release of PGE and PGI2 in the pump-perfused dog kidney and associated hypotension
JP2025537781A (ja) 中間分子量ヘパリンの調製
Li et al. Cross-linked inulin as a potential plasma expander: Biochemical properties and physiological characterization in a rabbit model
Dunn Physiological responses to burn injury and resuscitation protocols for adult major burns
EA048898B1 (ru) Фармацевтическая композиция, содержащая l-трийодтиронин (т3), для применения при лечении тканевой гипоксии и сепсиса
HK40088108A (zh) 用於治疗组织缺氧和脓毒症的包含l-三碘甲腺原氨酸(t3)的药物组合物
Dollins Part 2: Circulation
HK40088108B (zh) 用於治疗组织缺氧和脓毒症的包含l-三碘甲腺原氨酸(t3)的药物组合物
Drevyanko et al. A paper that will be submitted to J Surg Res Piper L. Wall, DVM; Norman F Paradise, PhD; Timothy F
Terblanche et al. Take home messages
Cross Characterisation of endothelial function in conduit and resistance arteries in chronic renal failure
Wierzbicki et al. r-. UE? AECTS OF OLUCCCCRTTCOXD RECEPTOR BLOCKADE O'. PI'. ONAPY?: RENAL VASCULAR PERMEABILITY IN SCALDED RATS H. Lin, X. 2> tong, and JG Zhong Dept, of Pathophysiology, Fuzhou

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180403